Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US

• Main Authors: Victoria Federico Paly (Author), Arvind Dasari (Author), Joleen Hubbard (Author), Tanios Bekaii-Saab (Author), Thihan Padukkavidana (Author), Luis Hernandez (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of t...